The world’s top 10 blockbusters — and what they tell us about R&D trends

In biopharma, the big R&D quest these days is building new blockbusters. And this list of the top 10 blockbusters drawn together for Nature Reviews Drug Discovery by EvaluatePharma illustrates why.

I’ll note here that this list isn’t quite accurate. You should probably call it the top 10 blockbusters sold by 1 company, as it overlooks partnered drugs. So Enbrel, with $7.1 billion from Amgen and Pfizer, doesn’t make the cut — though it should. There are others as well. But it still makes for an interesting review, especially if you want to look at the way these numbers are influencing R&D plans.

Most of these drugs got onto this list and stayed there by following a tried and true path to blockbuster creation: pushing annual price hikes that were gradually worth billions in new revenue. Just look at the top 2 cash cows, Humira and Revlimid, with close to $30 billion in combined sales. Europe blocked the price hike path years ago, and now the US is struggling to catch up but has clearly made an impression on the big players — watch out for those across-the-board price increases as you look to maximize your oil well, er, drug franchise, before time runs out.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 51,000+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->